en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2011
vol. 49
 
Share:
Send email
Share:
abstract:
Review paper

Certolizumab pegol in the treatment of rheumatoid arthritis

Piotr Wiland
,
Jerzy Świerkot
,
Włodzimierz Maśliński

Reumatologia 2011; 49, 4: 253–263
Online publish date: 2011/08/30
View full text Get citation
 
Recently a new drug inhibiting TNF, certolizumab pegol, has been produced and tested in numerous laboratory and clinical trials. Owing to pegylation (addition of polyethylene glycol to the Fab fragment of TNF neutralizing antibody) this molecule shows different properties in comparison to other TNF neutralizing drugs. The present paper describes similarities as well as differences in mechanisms of action, pharmacokinetics, metabolism, clinical efficacy, influence of radiological progression and safety of certolizumab in comparison to other biological drugs inhibiting TNF used for the treatment of patients with rheumatoid arthritis (Table I-III). The results of clinical trials revealed relatively fast response to certolizumab (Table II, Figure 1). In addition, it was possible to predict, with rather high probability, the long term efficacy of this drug, which may be important for pharmacoeconomics of the treatment.
keywords:

certolizumab pegol, methotrexate, rheumatoid arthritis, monotherapy, productivity
EVENTS/KONFERENCJE
BOOKS/KSIĄŻKI



Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.